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Abstract
To test the hypothesis that concomitant targeting of the epidermal growth factor receptor (EGFR) and transforming growth
factor-beta (TGF-b) may offer a novel therapeutic approach in pancreatic cancer, EGFR silencing by RNA interference
(shEGFR) was combined with TGF-b sequestration by soluble TGF-b receptor II (sTbRII). Effects on colony formation in 3-
dimensional culture, tumor formation in nude mice, and downstream signaling were monitored. In both ASPC-1 and T3M4
cells, either shEGFR or sTbRII significantly inhibited colony formation. However, in ASPC-1 cells, combining shEGFR with
sTbRII reduced colony formation more efficiently than either approach alone, whereas in T3M4 cells, shEGFR-mediated
inhibition of colony formation was reversed by sTbRII. Similarly, in vivo growth of ASPC-1-derived tumors was attenuated by
either shEGFR or sTbRII, and was markedly suppressed by both vectors. By contrast, T3M4-derived tumors either failed to
form or were very small when EGFR alone was silenced, and these effects were reversed by sTbRII due to increased cancer
cell proliferation. The combination of shEGFR and sTbRII decreased phospho-HER2, phospho-HER3, phoshpo-ERK and
phospho-src (Tyr416) levels in ASPC-1 cells but increased their levels in T3M4 cells. Moreover, inhibition of both EGFR and
HER2 by lapatinib or of src by SSKI-606, PP2, or dasatinib, blocked the sTbRII-mediated antagonism of colony formation in
T3M4 cells. Together, these observations suggest that concomitantly targeting EGFR, TGF-b, and src may constitute a novel
therapeutic approach in PDAC that prevents deleterious cross-talk between EGFR family members and TGF-b-dependent
pathways.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related mortality in the United States, with a 5-
year survival rate of 6% [1]. These dismal statistics are due, in
part, to the advanced stage of the cancer at presentation, a low
rate of resectability, multiple molecular alterations that promote
pancreatic cancer cell growth and survival, marked chemoresis-
tance, and intense desmoplasia which attenuates drug penetration
[2–5]. PDAC is associated with a high frequency of mutations in
the K-ras oncogene (95%), and the p16 (85%), p53 (75%) and
SMAD4 (55%) tumor suppressor genes [4]. Moreover, when p16
gene is not mutated, it is epigenetically silenced [6]. There is also
elevated expression of the epidermal growth factor (EGF) receptor
(EGFR), other tyrosine kinase receptors and their ligands, and
transforming growth factor beta (TGF-b) isoforms [7]. EGFR
mediates cell-autonomous mitogenic and motogenic signaling
cascades by activating diverse pathways, including mitogen
activated protein kinase (MAPK), p38 MAPK, and jun kinase
(JNK), whereas TGF-b activates Smad-dependent and -indepen-
dent signaling and is believed to exert paracrine effects on cells
within the tumor mircroenvironment in PDAC [8–10].
Excessive EGFR activation and dysfunctional signaling by
TGF-b receptor (TbR)-dependent pathways, as observed in
PDAC, generates multiple aberrant autocrine and paracrine
interactions between the cancer cells and the tumor microenvi-
ronment that contribute to tumor desmoplasia and that may
intersect with one or another of the dozen signaling cascades that
are implicated in the majority of PDACs [5,11]. Disappointingly,
targeting EGFR only slightly prolongs the survival of patients with
PDAC, and only when given in conjunction with gemcitabine
[12], whereas anti-TGF-b therapies for PDAC are currently being
developed and tested in pre-clinical studies [13–15].
We recently established a 3-dimensional culture system in which
cells are embedded in Matrigel consisting of 3% collagen IV/
laminin-enriched gelatinous medium and placed over a solidified
layer of soft agar [16]. We determined that concomitant treatment
with TGF-b1 and EGF enhanced growth in this 3-D model system
to a greater extent than either growth factor alone, and conferred
increasedchemoresistancetocytotoxiccompounds[16].Moreover,
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39684pharmacological inhibition of TbRI with SB431542 or EGFR with
erlotinib enhanced the efficacy of gemcitabine and cisplatin in
human pancreatic cancer cells and in primary cell cultures
established from pancreata of genetically-engineered mouse models
ofPDAC[16],underscoringtheusefulnessofthis3-Dculturesystem
for testing the efficacy of therapeutic agents.
In view of the importance of EGFR and TGF-b in PDAC, we
sought to test the hypothesis that targeting both pathways may
exert beneficial growth-suppressive effects that are greater than
suppressing either pathway alone. Because small molecule
inhibitors that target EGFR and TbRI may exert non-specific
effects and/or may target closely related kinases, we used a more
specific approach consisting of a silencing strategy to suppress
EGFR expression and a soluble TbRII strategy to sequester TGF-
b ligands. We now report that simultaneous suppression of both
pathways attenuated colony formation of ASPC-1 human
pancreatic cancer cells grown in 3-D culture and tumor growth
in vivo, but targeting TGF-b reversed the growth-inhibitory effects
exerted by EGFR silencing in T3M4 human pancreatic cancer
cells, and this reversal occurred in conjunction with src activation
as reflected by increased src phosphorylation on tyrosine 419.
Results
Effects of EGFR Knockdown and sTbRII Expression on
Colony Formation
Human pancreatic cancer cell lines express transforming growth
factor alpha (TGF-a) and other growth factors that activate EGFR
[17–19], as well as all three TGF-bs [20]. To determine whether
abrogating EGFR and TGF-b signaling modulated the growth of
such cell lines, ASPC-1 and T3M4 cells were co-infected at an
m.o.i. of 10 for each virus with shRNA-lentivirus targeting
Luciferase (shLuc-LV with pWPT-GFP), EGFR (shEGFR-LV
with pWPT-GFP), sTbRII (hLuc-LV with pWPT-sTbRII), or
both EGFR and sTbRII (shEGFR-LV with pWPT-sTbRII).
shEGFR-LV efficiently suppressed EGFR levels, whereas pWPT-
sTbRII expression was associated with the presence of abundant
levels of sTbRII protein in the medium in all four cell lines
(Fig. 1A).
The consequences of EGFR silencing and TGF-b sequestration
were assessed next by monitoring colony formation in a 3-D
culture assay in which Matrigel provides an acellular scaffold and
soft agar supports anchorage-independent growth [16]. We chose
to use this 3-D model system since we have previously shown that
concomitant treatment with TGF-b1 and EGF in this model
enhanced growth to a greater extent than either growth factor
alone [16], thereby recapitulating TGF-b‘s tumor promoting
effects previously demonstrated in xenograft and orthotopic mouse
models of PDAC [13–14]. Colony formation with ASPC-1 cells
infected with pWPT-sTbRII or shEGFR-LV was decreased by
21% (p,0.05) and 33% (p,0.01), respectively, whereas infection
with both shEGFR-LV and pWPT-sTbRII resulted in a 56%
(p,0.01) decrease in colony number by comparison with shLuc-
expressing ASPC-1 cells (Fig. 1B). By contrast, after infection with
shEGFR-LV, colony formation by T3M4 cells was decreased by
45% (p,0.05), whereas pWPT-sTbRII attenuated colony forma-
tion in T3M4 cells by 27% (p,0.05). However, pWPT-sTbRII
completely reversed the inhibitory actions of shEGFR-LV on
colony formation (Fig. 1B). Thus, ASPC-1 cells exhibited
synergistic inhibitory effects on colony formation when infected
with both shEGFR-LV and pWPT-sTbRII, whereas in T3M4
cells there was paradoxical reversal by pWPT-sTbRII of the
inhibitory actions of shEGFR-LV.
To determine whether other pancreatic cancer cell lined that
behaves like T3M4 cells, we next performed the colony forming
assay detailed in COLO-357 and PANC-1 pancreatic cancer cells
(Fig. S1). COLO-357 cells were only growth inhibited in response
to concomitant EGFR knockdown and sTbRII expression. By
contrast PANC-1 cells were growth inhibited by EGFR knock-
down, but exhibited a reversal of this growth inhibitory effect in
the presence of sTbRII (Fig. S1).
In Vivo Effects of EGFR Knockdown and sTbRII Expression
We next examined the consequences of EGFR silencing and
sTbRII expression in a subcutaneous nude mouse tumor model, to
determine whether the paradoxical reversal of EGFR silencing
observed in the 3-D in vitro model also occurred in vivo. Compared
with tumors generated by ASPC-1 cells infected with shLuc-LV,
tumor volumes on day 24 were decreased by 36% (p,0.05) with
shEGFR-LV, 38% (p,0.05) with pWPT-sTbRII, and 85%
(p,0.01) with both vectors (Fig. 2A). Moreover, 2 of 8 mice
injected with pWPT-sTbRII-expressing ASPC-1 cells were tumor-
free. Dramatically, 4 of 8 mice injected with ASPC-1 cells
expressing both pWPT-sTbRII and shEGFR-LV were tumor-free
on day 24, and the remaining 4 tumors only became visible 21
days following injection of the cancer cells. In the case of T3M4-
derived tumors, experiments were terminated on day 16 due to
rapid tumor growth in two of the four groups. At this time point,
tumor volume was decreased by 37% (p,0.05) for cells infected
with pWPT-sTbRII and by 97% (p,0.01) for shEGFR-LV-
infected cells (Fig. 2B). By contrast, T3M4 cells infected with both
pWPT-sTbRII and shEGFR-LV formed large tumors, each of
which exhibited areas of necrosis (Fig. 2B).
Tumors arising from either ASPC-1 or T3M4 cells exhibited
abundant Ki-67 immunoreactivity and foci of CD-31-positive
endothelial cells (Fig. 3A). In ASPC-1-derived tumors, expression
of pWPT-sTbRII did not alter proliferation, whereas expression of
shEGFR-LV was associated with a 60% (p,0.05) decrease in both
Ki-67 and CD31 immunoreactivity, and expression of both
vectors caused a further decrease in Ki-67 (72%, p,0.01) and
CD31 (76%, p,0.01) immunoreactivity (Fig. 3A). In T3M4 cells,
expression of pWPT-sTbRII was associated with decreased
proliferation (40%, p,0.01) and angiogenesis (77%, p,0.01),
expression of shEGFR-LV did not significantly alter proliferation
but markedly decreased CD31 immunoreactivity (71%, p,0.01),
whereas expression of both vectors markedly increased cancer cell
proliferation (196%, p,0.01) in spite of a persistent decrease
(85%, p,0.01) in CD31 immunoreactivity (Fig. 3A).
In view of the presence of regions of necrosis in T3M4 tumors
expressing both pWPT-sTbRII and shEGFR-LV, it was impor-
tant to avoid spurious results that may occur in areas about to
undergo necrosis. Therefore, both the TUNEL assay and cleaved
PARP immunostaining were performed next to assess apoptosis,
both methods yielding generally concordant results (Fig. 3B).
Thus, pWPT-sTbRII did not significantly alter the percentage of
cells undergoing apoptosis in either ASPC-1 or T3M4-drived
tumors, whereas shEGFR-LV expression was associated with
a marked increase in apoptosis in ASPC-1 cells (p,0.01), but not
in T3M4 cells. Moreover, in ASPC-1-derived tumors, pWPT-
sTbRII did not alter shEGFR-LV-associated apoptosis, but in
T3M4-derived tumors it was associated with enhanced apoptosis
(Fig. 3B).
Effects of EGFR Knockdown and sTbRII Expression on
Phosphorylation State of EGFR Family Members
EGFR, HER2 and HER3 have all been implicated in the
pathobiologyofPDAC[7,21–23].SinceEGFRformsheterodimers
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silencingcouldmodulate signalingbytheseEGFRfamily members.
Therefore, ASPC-1 and T3M4 cell lysates were subjected to
immunoblotting to assess the levels of phospho-HER2, and
phospho-HER3(Fig.4A).Densitometricanalysisofdata fromthree
experimentsshowedthatpWPT-sTbRIIexpressioninASPC-1cells
induced a 17% and 20% decrease in phospho-HER2 and phospho-
HER3 levels, respectively (p,0.05), whereas EGFR knockdown
induced a 61% decrease in phospho-HER2 levels (p,0.01) and
a 30% decrease in phospho-HER3 (p,0.01) levels. ASPC-1 cells
expressingbothshEGFR-LVandpWPT-sTbRIIexhibitedasimilar
decrease in phospho-HER2 levels (52%, p,0.01), but a more
pronounced decrease in phospho-HER3 levels (56%, p,0.01). By
contrast, in T3M4 cells, pWPT-sTbRII did not alter phospho-
HER2 or phospho-HER3 levels, whereas EGFR knockdown was
associatedwithincreasedlevelsofbothphospho-receptors(Fig.4A).
In three experiments, there was a 60% increase in phospho-HER2
and phospho-HER3 levels in T3M4 cells following EGFR
knockdown, and 100% and 80% increases in phospho-HER2 and
phospho-HER3 levels, respectively, in cells expressing both vectors.
To determine whether HER2 and HER3 phosphorylation was
also modulated in vivo in T3M4 cells, tumors derived from these
cells were evaluated by immunohistochemsitry (Fig. S2). Moderate
phospho-HER2 immunoreactivity was evident in tumors from
cells infected with shLuc, and shEGFR-LV, which was decreased
in tumors infected with pWPT-sTbRII, but increased in tumors
Figure 1. EGFR knockdown and sTbRII expression modulate colony formation in pancreatic cancer cells. (A) ASPC-1 and T3M4 human
pancreatic cancer cells were infected with shLuc-LV (shLuc), shEGFR-LV (shEGFR), WPT-sTbRII (sTbRII), or both shEGFR and sTbRII. Cell lysates and
conditioned media were then subjected to immunoblotting with anti-EGFR and anti-HA-tag antibodies, respectively, the latter serving to confirm
sTbRII release by the cancer cells. An anti-ERK antibody served to assess lane loading. (B) The consequences of EGFR silencing with shEGFR and TGF-
b sequestration with sTbRII were assessed by monitoring colony formation in 3-D culture (B). Data are the means 6 SE of triplicate determinations
from three independent experiments. *p,0.05, **p,0.01, when compared with respective controls.
doi:10.1371/journal.pone.0039684.g001
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activity was low in tumors from shLuc-infected T3M4 cells,
slightly increased in pWPT-sTbRII-expressing tumors, moderately
increased in shEGFR-LV-expressing tumors, and markedly in-
creased in tumors expressing both vectors (Fig. S2). Thus, both
HER2 and HER3 are aberrantly activated in vivo in T3M4 cells
when both EGFR and TGF-b pathways have been targeted.
Effects of EGFR Knockdown and sTbRII Expression on
Downstream Signaling
ERK, src, and AKT are mitogenic and pro-survival signaling
modules that are downstream of EGFR family members and that
contribute to PDAC progression [12,24]. Therefore, ASPC-1 and
T3M4 cell lysates were subjected to immunoblotting to assess the
effects of EGFR knockdown and sTbRII expression on these
pathways (Fig. 4B). In ASPC-1 cells, shEGFR-LV, pWPT-sTbRII,
and their combination was associated with attenuated phospho-
ERK levels, but only the combination decreased phospho-AKT
levels whereas none of these transfection conditions induced the
de-phosphorylation of Src(Tyr527), which would be reflective of
src activation (Fig. 4B). By contrast, in T3M4 cells, shEGFR-LV
alone or in combination with pWPT-sTbRII resulted in increased
phospho-ERK and decreased phospho-src(Tyr527) levels, without
any alterations in phospho-AKT levels (Fig. 4B).
To confirm that the combination of shEGFR-LV and pWPT-
sTbRII activated src in T3M4 cells, lysates were also subjected to
a phospho-kinase antibody array. EGFR silencing led to inhibition
of the phosphorylation of src(Tyr419), Fyn, Hck, Lyn, Yes and
Fgr, which was especially pronounced with respect to src (Fig. 5).
By contrast, expression of sTbRII inhibited the phosphorylation of
Lyn Yes, and Fgr, without altering src, Fyn or Hck phosphory-
lation (Fig. 5). However, the inhibitory effects of shEGFR-LV on
all 6 kinases were completely reversed by sTbRII (Fig. 5),
indicating that expression of sTbRII reactivated src family kinases.
Effects of HER2 Silencing and src Inhibition on Colony
Formation in T3M4 Cells
We next sought to assess the role of HER2 in mediating the
deleterious effects of simultaneous targeting EGFR and TGF-b.A s
expected, shEGFR-LV markedly suppressed EGFR levels in
T3M4 cells, shHER2-LV markedly suppressed HER2 levels,
whereas infection with both vectors silenced the expression of both
EGFR and HER2 (Fig. S3). Moreover, T3M4 cells expressing
either shEGFR-LV or shHER2-LV exhibited a significant de-
crease in colony numbers in the 3-D assay (Fig. 6A). In the case of
shEGFR-LV, but not shHER2-LV or shEGFR-LV together with
shHER2-LV, this effect was reversed by pWPT-sTbRII (Fig. 6A).
Thus, concomitant infection with shEGFR-LV and shHER2-LV
markedly inhibited colony growth (66%, p,0.01). Similarly,
lapatinib (1 mM), a dual tyrosine kinase inhibitor that interrupts
HER2 and EGFR signaling pathways, reduced colony number by
47% (p,0.01) and prevented the reversal observed following co-
infection with shEGFR-LV and pWPT-sTbRII (Fig. 6).
In view of the up-regulation of phospho-src (Tyr419) and the
dephosphorylation of Src(Tyr527) by the combination of
shEGFR-LV and pWPT-sTbRII in T3M4 cells, we sought to
determine whether the deleterious effects of this combination
might be mediated by activated src. Therefore, the effects of
three distinct src inhibitors on colony formation in 3-D culture
were examined next. Only dasatinib (100 nM) significantly
inhibited the growth of T3M4 cells infected with shLuc-LV
(Fig. 6B). However, SKI-606 (1 mM), PP2 (1 mM), and dasatinib
(100 nM) completely blocked the pWPT-sTbRII-mediated re-
Figure 2. Targeting EGFR and TGF-b pathways exerts different effects on the formation and growth of tumors formed by ASPC-1
and T3M4 cells. ASPC-1 (A) and T3M4 (B) cells were infected with shLuc-LV (shLuc), shEGFR-LV (shEGFR), sTbRII, or both EGFR-LV and sTbRII, and
injected subcutaneously (one injection per mouse) into the flank region of nude mice. Tumor volumes were monitored for the indicated number of
days. Values are the means 6 SEM of 8 mice per group, indicated in the denominator to the right of each curve. The number of tumors that formed in
each group is indicated in the numerator. *p,0.05, and **p,0.01, when compared with respective controls.
doi:10.1371/journal.pone.0039684.g002
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indicating that this effect was dependent on src kinase activity.
Discussion
Members of the EGF family, including TGF-a, heparin-binding
EGF-like growth factor (HB-EGF), betacellulin, and amphiregulin,
are expressed at high levels in PDAC and act on the cancer cells in
PDAC and on the adjoining stromal elements [7]. EGFR
activation by these ligands initiates multiple signaling cascades,
such as Ras/Raf/MAPK and Rac/JNK/MAPK-p38 [24]. EGFR
heterodimerization with other members of the EGFR family leads
to the activation of other signaling pathways that include Src,
Raf1, B-Raf, Crk, and Nck, which further promote tumor
progression and biological aggressiveness [25]. EGFR cross talk
with multiple pathways is enhanced by the high frequency of Kras
and Smad4 mutations, and by the abundance of TGF-b which
alters the extracellular matrix in a manner that promotes cancer
cell growth, induces aberrant epithelial-mesenchymal interactions,
enhances angiogenesis, and promotes metastasis [4–7,10,13–
14,26–27]. Moreover, TGF-b synergizes with EGF in promoting
proliferation in 3-D culture [16]. Together, these observations
Figure 3. Effects of targeting EGFR and TGF-b pathways on proliferation, angiogenesis and apoptosis. A. The ASPC-1- and T3M4-
derived tumors described in figure 2 were immunostained for Ki67 to assess proliferation and CD31 to assess angiogenesis. B. The same tumors were
scored for TUNEL-poisitive cells and cleaved PARP immunoreactivity to assess apoptosis. Data are the means 6 SEM of triplicate determinations from
three independent experiments. *p,0.05, and **p,0.01, when compared with respective controls.
doi:10.1371/journal.pone.0039684.g003
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pathways are pivotal in promoting pancreatic cancer progression
and may represent crucial therapeutic targets in PDAC.
In the present study we demonstrated that lentiviral-based
silencing of EGFR efficiently attenuated its pro-mitogenic actions
in 3 of 4 pancreatic cancer cell lines, and that lentiviral-based
sequestration of TGF-b also attenuated proliferation in 3-D
culture in the same three cell lines. However, in ASPC-1 and
COLO-357 cells, concomitantly silencing EGFR and sequestering
TGF-b resulted in enhanced growth suppression, whereas in
T3M4 and PANC-1 cells there was nearly complete reversal of the
growth-suppressive effects of EGFR down-regulation. Under
standard tissue culture conditions, ASPC-1 and T3M4 cells are
resistant to TGF-b-mediated growth inhibition, whereas COLO-
357 and PANC-1 cells are growth-inhibited by TGF-b [19,28].
Thus, the observed paradoxical reversal cannot be attributed to
differences in the growth-inhibitory responsiveness of the cancer
cells. Instead, in T3M4 cells, this reversal is due, in part, to the up-
regulation of phospho-HER2 and phospho-HER3 elicited by
EGFR downregulation and enhanced in the presence of sTbRII.
In agreement with this conclusion, the growth-inhibitory effects
induced by silencing HER2 or both EGFR and HER2 were not
reversed by sTbRII. Similarly, lapatinib, which inhibits both
EGFR and HER2 kinase activities, also inhibited the growth of
T3M4 cells and this effect was resistant to sTbRII-mediated
reversal. ERK can be activated by multiple upstream signals, and
increased HER2/3 phosphorylation in T3M4 cells was associated
in the present study with increased ERK phosphorylation,
indicating that HER2/3 downstream signaling was also being
activated.
Several lines of evidence suggest that src activation mediated by
TGF-b sequestration is also crucial for the reversal phenomenon.
First, src inhibition by EGFR silencing was completely reversed by
TGF-b sequestration. Second, EGFR Signaling is known to
activate src [29], and src activation is known to induce the release
of the precursors of EGF-like ligands [6] and attenuate EGF
internalization [29,30]. These mechanisms may promote EGFR
heterodimerization with HER2 and HER3, thereby further
enhancing mitogenic signaling. Third, sTbRII increased the levels
of src phosphorylation on tyrosine residue 419 in T3M4, and
phosphorylation at this site correlates with increased src activity.
Moreover, sTbRII did not alter the phosphorylation of
Src(Tyr527) in ASPC-1 cells, but decreased its phosphorylation
in T3M4 cells in the absence and presence of shEGFR, confirming
that src was being activated in T3M4 cells by sTbRII. Fourth,
three src kinase inhibitors, SKI-606, PP2, and dasatinib, blocked
the TbRII-mediated reversal of growth inhibition.
We have previously determined that addition of purified sTbRII
protein to the medium of these cells also sequesters TGF-b and
blocks TGF-b actions in vitro (unpublished observations). TGF-
b binds to type II TGF-b receptor (TbRII) homodimer, which
then forms a heterotetrameric complex with the TbRI homo-
dimer, leading to the activation of TbRI serine-threonine kinase
activity [9]. This activation initiates a signaling cascade that
includes the phosphorylation of receptor-regulated Smads (R-
Smads), Smad2 and Smad3, at their C-terminal SSXS motif, their
subsequent oligomerization with the common mediator Smad4,
and translocation of the complex to the nucleus where regulation
of gene transcription is then effected [9,31]. TbRII can also be
phosphorylated on tyrosine residue 284 leading to the activation of
alternate pathways such as p38 MAPK [32]. While src activation
often occurs downstream of tyrosine kinase receptors, TGF-b may
also increase src activity, but in a transient manner [33]. However,
TGF-b also acts to induce src degradation [34]. It is possible,
therefore, that TGF-b sequestration in T3M4 cells may prevent
cancer cell-derived TGF-b from inducing src degradation and/or
inactivation.
To assess the biological relevance of these in vitro findings, we
used a subcutaneous nude mouse model which allows for
reproducible assessment of the in vivo biological relevance of
signaling pathways that are altered in vitro. Thus, with respect to
ASPC-1 cells, either EGFR down-regulation or TGF-b sequestra-
tion resulted in significant (36 to 38%) decreases in tumor volume,
with a further decrease to 85% when both approaches were
combined. Impressively, tumors failed to form in 2 of 8 mice
injected with ASPC-1 cells expressing pWPT-sTbRII, and in 4 of
8 mice expressing both pWPT-sTbRII and shEGFR-LV. More-
over, there was a marked delay in the appearance of the 4 tumors
Figure 4. Effects of EGFR knockdown and sTbRII expression on
receptor phosphorylation and downstream signaling. (A) Effects
on receptor phosphorylation. ASPC-1 and T3M4 cells were infected as
indicated with shLuc-LV (shLuc), shEGFR-LV (shEGFR), WPT-sTbRII
(sTbRII), or both shEGFR and sTbRII. Cell lysates were subjected to
immunoblotting with antibodies directed against the indicated
receptors and phospho-receptors. (B) Cells were infected as indicated
in A, and cell lysates were subjected to immunoblotting with antibodies
directed against the indicated proteins and phospho-proteins. Each
panel shows data from a representative of at least two independent
experiments. In both panels A and B, immnoblotting with an anti-ERK
antibody confirmed equivalent lane loading, but not all ERK blots are
shown.
doi:10.1371/journal.pone.0039684.g004
EGFR and TGF-beta Targeting in Pancreatic Cancer
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39684that arose from cells expressing both pWPT-sTbRII and shEGFR-
LV, all of which exhibited greatly decreased proliferation and
angiogenesis, and increased apoptosis. These findings support
strategies for targeting TGF-b in PDAC [13,14,35], and are
consistent with the observation that there is a strong EGFR in situ
hybridization signal in the tumor vasculature in PDAC in humans
[36] and with proposed roles of EGFR in tumor angiogenesis.
While targeting TGF-b by ligand sequestration or by TbRI kinase
inhibition attenuates pancreatic tumor growth and metastasis in
mouse models [13–15], our findings indicate that, in certain
instances, targeting both EGFR and TGF-b-dependent pathways
can exert synergistic inhibitory effects on PDAC proliferation and
angiogenesis.
In T3M4-derived tumors, TGF-b sequestration resulted in
a 37% decrease in tumor volume and decreased proliferation and
angiogenesis, whereas EGFR down-regulation resulted either in
the failure to form tumors or in the formation of exceedingly small
tumors and markedly attenuated angiogenesis. Thus, T3M4 cells
are highly dependent on EGFR for tumor initiation, progression
and angiogenesis in vivo, and this exquisite dependence on EGFR is
consistent with EGFR-mediated mitogenesis as well as with its role
in angiogenesis-dependent oncogene addiction [37,38]. These
dramatic effects were reversed by sTbRII which restored pro-
liferation but did not alter angiogenesis or apoptosis, resulting in
large tumors that exhibited foci of necrosis. Thus, while the in vitro
and in vivo growth inhibitory actions of EGFR silencing were
reversed by TGF-b sequestration, the paracrine anti-angiogenic
effects of EGFR silencing and effects on apoptosis persisted,
underscoring the pro-mitogenic effects of src activation. Moreover,
it has been recently demonstrated that angiogenesis is important in
a Kras-driven genetically engineered mouse model of PDAC [39]
and that variant 161R form of interlukin-17F (IL-17F), which is
a natural antagonist of the anti-angiogenic effects of wild-type
161H IL-17F, is associated with a worse prognosis in PDAC [40],
providing indirect evidence that angiogenesis may play an
important role in its metastatic spread. In view of these
observations, the current findings suggest that targeting EGFR
and TGF-b may be important for normalizing tumor angiogenesis
in the primary tumor and suppressing angiogenesis in metastatic
lesions in PDAC.
ASPC-1 and T3M4 cells harbor mutated KRAS and p53 genes,
and express high EGFR levels [5,41]. These cells also produce
high levels of TGF-b, TGF-a and amphiregulin [19,42], which are
auto-inducible, TGF-b-inducible, and pro-angiogenic. Moreover,
ASPC-1 cells harbor a mutated SMAD4 gene [43], whereas
T3M4 cells are wild type for Smad4 [44]. As such, ASPC-1 and
T3M4 cells exhibit alterations that are highly representative of the
spectrum of typical molecular alterations seen in PDAC. In spite of
the presence of oncogenic Kras in ASPC-1 cells, the concomitant
targeting of EGFR and TGF-b provided an effective therapeutic
strategy in these cells, suggesting that targeting two key upstream
events in PDAC may overcome therapeutic resistance engendered
by oncogenic Kras in some pancreatic cancer cells. However, as
evidenced in T3M4 cells, targeting both EGFR and TGF-b can
also lead to deleterious effects as a consequence of HER2/3 and
src activation. Inasmuch as src may be an important mediator of
cross-talk between EGFR family members and several growth-
modulating pathways such as Met, Notch-1 and furin [45–47], our
findings suggest that concomitantly targeting the activation of cell-
surface receptors such as EGFR, HER2, and TbRI and the
intracellular src kinase may represent a novel strategy for
suppressing pancreatic cancer growth in the presence of oncogenic
Kras.
It has been recently demonstrated that most cases of PDAC
develop slowly over approximately two decades before acquiring
the capacity to metastasize [48,49]. Moreover, targeting TGF-b in
an orthotopic murine model of PDAC markedly suppresses
metastasis [14]. Together with the current findings, these
observations also raise the possibility that combinatorial targeted
therapy aimed at EGFR, TGF-b, and src may constitute a novel
approach in PDAC that interferes with multiple signalling
components downstream of EGFR and TbR, attenuating disease
progression while preventing potentially deleterious cross-talk
between these pathways. Moreover, targeting these pathways
Figure 5. Effects of targeting EGFR and TGF-b pathways on phosphorylation status of src family members. T3M4 cells were infected
with shLuc-LV (shLuc), shEGFR-LV (shEGFR), and/or WPT-sTbRII (sTbRII) as indicated. Cell lysates were then analyzed with a phospho-kinase antibody
array to assess the phosphorylation status of the indicated src family members. Results were quantified as described in Methods. Data are the means
6 SEM of triplicate determinations from three independent experiments. *p,0.05, **p,0.01, and ***p,0.001 when compared with control.
doi:10.1371/journal.pone.0039684.g005
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allowing for improved drug delivery within the tumor mass. In
theory, therefore, delivery of lentiviral vectors into the pancreatic
tumor mass via endoscopic ultrasonography administered prior to
the presence of metastatic disease in conjunction with the systemic
administration of a small molecule src inhibitor could prove to be
an effective approach in PDAC. Antibodies or small molecule
inhibitors that target both EGFR and TGF-b pathways given
together with a src inhibitor could also be used even when
metastatic disease is present, perhaps followed by the addition of
chemotherapeutic agents such as gemcitabine. It will now be
important to conduct additional pre-clinical testing of these
approaches and to delineate specific biomarkers to indicate which
subgroups of PDAC patients would be responsive to this form of
combinatorial therapy.
Material and Methods
Cell Culture
ASPC-1 and PANC-1 human pancreatic cancer cells were
obtained from ATCC (Manassas, VA), whereas T3M4 and
COLO-357 human pancreatic cancer cells were a gift from R.
Metzger (Duke University). Both T3M4 and COLO-357 cells
were originally isolated from PDAC metastases [50–51]. ASPC-1
and T3M4 cells were grown in RPMI (Mediatech Inc., Herndon,
VA). COLO-357 and PANC-1 cells were grown in DMEM.
Media were supplemented with 10% fetal bovine serum (FBS)
Figure 6. Effects of HER2 silencing, lapatinib, and src inhibition on sTbRII-mediated reversal of growth suppression. A. HER2 silencing
and inhibition. T3M4 cells were infected with shLuc-LV (shLuc), shEGFR-LV (shEGFR), shHER2-LV (shHER2), or both shEGFR and shHER2, in the absence
or presence of WPT-sTbRII (sTbRII) or 1 mM lapatinip. Colony formation was monitored in 3-D culture. Data are the means 6 SEM of triplicate
determinations from three independent experiments. *p,0.05, and **p,0.01, when compared with control. B. Effects of c-Src inhibition. T3M4 cells
were incubated in the absence or presence of the src kinase inhibitors SKI-606 (1 mM), PP2 (1 mM) and dasatinib (100 nM), and effects on colony
formation in 3-D culture were determined. Data are the means 6 SE of triplicate determinations from three independent experiments. *p,0.05,
**p,0.01, when compared with respective controls.
doi:10.1371/journal.pone.0039684.g006
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penicillin and 100 mg/ml streptomycin.
Vector Construction
The soluble type II TGF-b receptor construct (pWPT-sTbRII)
encodes a fusion protein consisting of the extra cellular domain
(amino acid residues 1-477) of TbRII fused with an Ig Fc tail and
an HA-tag. The construct encoding the tagged fusion protein was
subcloned into XhoI sites from a lentivirus plasmid pWPT-GFP
(Addgene, Cambridge, MA), replacing the GFP gene. The
recombinant pWPT-sTbRII and pWPT-GFP plasmids were
propagated in E. coli top ten competent cells (Invitrogen, Carlsbad,
CA). Authenticity was confirmed by sequencing, and sTbRII
expression was assessed by immunoblotting for HA (Cell
Signaling, Danvers, MA).
To prepare the shRNA targeting EGFR, a pool of siRNA
sequences directed against EGFR (Dharmacon, Lafayette, CO)
were transfected into ASPC-1 cells using Jet PEI (Qbiogene,
Solon, OH) according to the manufacturer’s protocol. The
siRNA pool efficiently silenced EGFR protein expression, and
each sequence was then tested to select the most efficient siRNA
sequences for designing the oligonucleotides for the shRNA
targeting EGFR. The same procedure was used to target human
EGFR 2 (HER2) and luciferase (negative control). Oligonucleo-
tides were annealed and cloned into pLentiLox 3.7 (pll3.7)
(Addgene, Cambridge, MA), yielding highly efficient lentiviral
vectors carrying the shRNA targeting EGFR (shEGFR-LV),
HER2 (shHER2-LV) or Luciferase (shLuc-LV). Virus stocks were
prepared by co-transfecting pll3.7 with three packaging plasmids
(pMDLg/pRRE, CMV-VSVG and RSV-Rev) into 293T cells
[52]. Viral supernatants were harvested 36–48 hours later,
filtered and centrifuged (90 min at 25,000 X g). Viral titers were
determined by fluorescence-activated analysis (FACS) analysis
and all cells were infected at a multiplicity of infection (m.o.i.) of
10.
Colony Formation in 3-Dimensional Matrigel Assays
A 3-dimensional (3-D) cell culture system was used to assess
colony formation, as reported previously [16]. Briefly, cells
(2,000 per well) were suspended in 3% growth factor reduced
(GFR) Matrigel (BD Biosciences, San Jose, CA), dissolved in
0.2 ml of medium containing 5% FBS, and plated on top of
solidified 0.2 ml of 1% noble agar in the same medium, using
48-well culture plates. Medium (0.2 ml) containing 3% GFR
Matrigel and 5% FBS was added every 3 days, in the absence or
presence of lapatinib (1 mM), SKI-606 (1 mM), PP2 (1 mM) and
dasatinib (0.1 mM). After 2 weeks, colonies were stained by
incubating for 4 hours with of 3-4,5-dimethylhiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St Louis,
MO) and counted.
Immunoblotting
Immunoblotting was performed as reported previously [13],
using PVDF membranes (Perkin Elmer, Boston, MA). Membranes
were incubated overnight with the following primary antibodies:
anti-EGFR (15F8) (#4405), anti-phospho-EGFR (Tyr845)
(#2231), anti-phospho-HER2 (Tyr1221/1222) (#2243), anti-
phospho-HER3 (Tyr1289) (#4791), anti-HA-Tag (#2367), and
anti-phospho-src(Tyr527) all form Cell Signaling Technology
(Danvers, MA; 1:500 to 1:1000 dilution); and anti-HER2 (#06-
562) and anti-HER3 (#05-390) from Upstate Biotechnology, Lake
Placid, NY). The membranes were washed, incubated for 30
minutes with secondary horseradish peroxidase-conjugated anti-
body (Biorad, Hercules, CA), and bound antibodies were
visualized using enhanced chemiluminescence (Pierce, Rockford,
IL). Membranes were stripped and blotted with a 1:10,000
dilution of rabbit anti-ERK antibody (Santa-Cruz Biotechnology,
Santa Cruz, CA).
Tumorigenicity Assay
To assess effects on tumorigenicity, 1 x10
6 ASPC-1 cells and
0.5 x10
6 T3M4 cells expressing shLuc-LV, shEGFR-LV, pWPT-
sTbRII, or both shEGFR-LV and pWPT-sTbRII, were injected
subcutaneously into the flank region of 6–8 week-old, female,
athymic nude mice (Harlan, Indianapolis, IN). Fewer T3M4 cells
were used because these cells form rapidly growing tumors.
Studies with mice were approved by Dartmouth Medical School
and Indiana University School of Medicine Institutional Animal
Care and Use Committees. Mice were monitored twice weekly
and sacrificed 8–15 weeks after injection when tumor diameter
reached a maximally allowable 15 mm. Tumor volumes were
calculated as p/4 6width 6height 6length of the tumor [13].
Immunohistochemistry and TUNEL Assay
Following rapid tumor removal, tissues were cryo-embedded in
cryo-OCT compound (Fisher Scientific, Pittsburgh, PA). All
immunohistochemistry experiments were done as described pre-
viously [53] using an anti-Ki-67 antibody (Abcam, Cambridge,
MA; 1:50 dilution) to assess proliferation, anti-CD31 to detect
endothelial cells (PharMingen, San Jose, CA) and anti-cleaved
PARP (#9141) (Cell Signaling Technology, Danvers, MA) to
assess apoptosis. Phospho-HER2 and phospho-HER3 immunore-
activity was determined using the respective anti-phospho
antibodies described above. Quantitative morphometry (10
areas/slide) was performed as reported previously [53], using an
Olympus DP70 camera (100 X magnification), and quantified
with the Image-Pro plus program (Version 4.51, Media cybernet-
ics, L.P., Silver Spring, MD).
Apoptotic cells were also detected by measuring DNA
fragmentation using the deoxynucleotidyl transferase-mediated
dUTP nick-end labelling (TUNEL) method (In Situ Cell Death
Detection Kit, POD, Roche Applied Science, Indianapolis, IN),
according to the manufacturer’s protocol. Sections were incubated
with peroxidase-conjugated anti-digoxigenin antibody for 30 min
at 23uC to detect digoxigenin-dUTP labelling, and for 5 min in
a solution of 0.05% 3,39-diaminobenzidine (DAB, Vector Labo-
ratories, Burlingame, CA) and 0.01% H2O2. In all immunostain-
ing and TUNEL assays, three randomly selected tumors per group
were analyzed.
Phospho-kinase Array
T3M4 cells were analyzed in a panel of phosphorylation profiles
of kinases (Human Phospho-Kinase Array, ARY003; R&D
Systems, Minneapolis, MN). A cocktail of biotinylated detection
antibodies, streptavidin–horseradish peroxidase and chemilumi-
nescent detection reagents were used to detect the phosphorylated
protein. The relative expression of specific phosphorylated
proteins was determined following quantification of scanned
images by Image-Pro plus program.
Statistical Analysis
Data were analysed using either ANOVA or the Kruskall and
Wallis tests for mean comparisons, using the Dunn-Benferroni test
for multiple comparisons. p,0.05 was taken as the level of
significance.
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Figure S1 COLO-357 and PANC-1 human pancreatic
cancer cells were infected with shLuc-LV (shLuc),
shEGFR-LV (shEGFR), WPT-sTbRII (sTbRII), or both
shEGFR and sTbRII, and the consequences of EGFR
silencing with shEGFR and TGF-b sequestration with
sTbRII were assessed by monitoring colony formation in
3-D culture. Data are the means 6 SE of triplicate determina-
tions from three independent experiments. *p,0.05, **p,0.01,
when compared with respective controls.
(EPS)
Figure S2 T3M4 cells were infected with shLuc-LV
(shLuc), shEGFR-LV (shEGFR), sTbRII, or both EGFR-
LV and sTbRII, and injected subcutaneously into the
flank region of nude mice. Tumor immunoreactivity for
phospho-HER2 and phospho-HER3 was determined 16 days later
using the indicated anti-phospho antibodies. Scale bars, 50 mm.
(EPS)
Figure S3 T3M4 cells were infected with shLuc-LV
(shLuc), shEGFR-LV (shEGFR), shHER2-LV (shHER2)
or a combination of shEGFR and shHER2, in the
absence or presence of WPT-sTbRII (sTbRII). Immuno-
blotting was then carried out with antibodies directed against the
indicated proteins. Data shown are from a representative of three
experiments.
(EPS)
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